Founder and CEO, MarksMan Healthcare Communications and KYT Adhere, H No 9-1-67, Plot 67, Behind Q City, Hyderabad, INDIA.
Senior Consultant, Medical Writing and Biostatistics, MarksMan Healthcare Communications, H No 9-1-67, Plot 67, Behind Q City, Hyderabad, INDIA.
Indian J Med Ethics. 2020 Jul-Sep;V(3):202-207. doi: 10.20529/IJME.2020.068.
The world is going through an unprecedented medical emergency with no effective remedy for the SARS-CoV2 virus causing Covid-19. Two drugs used for other indications in the past, hydroxychloroquine (HCQ) and remdesivir (RDV), are sought to be repurposed to treat Covid-19. Both these drugs have received emergency use authorisation by the US Food and Drug Administration. In this review, we critically analyse the identification of and subsequent events concerning these two drugs as potential treatment options for Covid-19, and conclude by raising some ethical issues that require serious thought from the global scientific community concerned with using these two drugs against Covid-19.
Key Words: Covid-19, hydroxychloroquine, remdesivir, USFDA, emergency use authorisation
.
世界正面临着一场前所未有的医疗紧急情况，对于导致 COVID-19 的 SARS-CoV2 病毒尚无有效的治疗方法。过去用于其他适应症的两种药物，羟氯喹（HCQ）和瑞德西韦（RDV），被寻求重新用于治疗 COVID-19。这两种药物均已获得美国食品和药物管理局的紧急使用授权。在本次综述中，我们批判性地分析了这两种药物作为 COVID-19 潜在治疗选择的鉴定和随后的事件，并得出结论，提出了一些需要全球关注 COVID-19 治疗的科学界认真思考的伦理问题。
关键词：COVID-19，羟氯喹，瑞德西韦，美国食品和药物管理局，紧急使用授权
。
